Lessons coming from an unfavorable gene therapy trial for Duchenne muscle dystrophy

.Attribute Medication, Posted online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec got FDA permission after an adverse trial, which highlights the many difficulties and problems of medication development in this setup.